Understanding the Search Behind "Why Choose CRET Technology"
When healthcare professionals, laboratory directors, and diagnostic distributors ask why they should choose CRET technology, they are typically looking for a clear explanation of what sets this platform apart from conventional chemiluminescence immunoassay (CLIA) methods, and how it translates into practical, measurable benefits for clinical and point-of-care settings. Nanjing Poclight Biotechnology Co., Ltd., operating under the brand name Poclight Biotechnology, has built its entire diagnostic platform around this exact question, positioning its patented Chemiluminescence Resonance Energy Transfer (CRET) technology as the foundation of a fifth-generation In Vitro Diagnostic (IVD) system.
What Is CRET Technology and Why Does It Matter
CRET, short for Chemiluminescence Resonance Energy Transfer, is a proprietary, no-wash, no-separation homogeneous immunoassay platform developed by Poclight. Unlike traditional magnetic bead-based chemiluminescence systems, which require multiple washing and separation steps to isolate bound and unbound reagents, CRET technology relies on a homogeneous method that eliminates these procedural steps entirely. The platform uses Acridine Ester and Graphene Oxide quenching to achieve high sensitivity without the need for magnetic beads, representing the core mechanism behind Poclight's fifth-generation chemiluminescence platform.
This distinction matters because traditional CLIA systems often involve operational complexity tied to liquid paths and washing cycles. These steps consume time, introduce potential points of failure, and require ongoing maintenance. By removing them altogether, CRET technology directly addresses one of the most persistent pain points in diagnostic testing: the slow turnaround times that hinder emergency and point-of-care settings.
The Direct Value of Choosing CRET Technology
Poclight identifies several concrete advantages that stem from its CRET platform, each tied to a specific industry challenge.
First, the no-wash, no-separation process delivers a 70% reduction in time and expenditure compared to conventional immunoassay procedures. This efficiency gain is particularly relevant in clinical testing environments where rapid decision-making is critical, such as emergency departments and intensive care units.
Second, because CRET-based reagents do not require the same handling as traditional reagents, Poclight has been able to develop room-temperature stable lyophilized reagent solutions in a spherical bead format. These reagents remain stable at 2-30°C for 18 months, which eliminates the need for cold chain logistics. This directly resolves the high logistics costs that have long burdened traditional reagent distribution, resulting in a 50% reduction in logistics costs for global shipping scenarios.
Third, the absence of internal liquid paths means that instruments built on the CRET platform, such as the C5000 Micro-Chemiluminescence Immunoassay Analyzer, require no hidden cleaning or consumable costs. This maintenance-free design removes a recurring expense that many laboratories associate with traditional CLIA systems.
Fourth, CRET technology enables significant hardware simplification. The C5000 analyzer, built on this platform, weighs approximately 8.5kg, an 80% weight reduction compared to traditional analyzers, and fits within an A4 footprint. This addresses the space constraints commonly experienced in small clinics and decentralized health centers.
A Technology With Verified Market Recognition
According to Poclight, the company holds the distinction of being the sole company worldwide with an authorized CRET patent for IVD use. This proprietary status is reinforced by a set of third-party certifications, including CE Certification, ISO 13485 Certification, NMPA certification, and NGSP certification. These qualifications provide an objective layer of validation for organizations evaluating the platform's reliability and regulatory compliance.
The technology has also been developed within a structured innovation environment, with R&D activities associated with the Suzhou biopharmaceutical valley accelerator, reflecting the company's positioning as a high-growth R&D enterprise within the IVD sector.
How CRET Technology Performs in Real Clinical Settings
Poclight's CRET-based instruments and reagents have been applied across several documented use cases that illustrate the practical impact of the technology.
In emergency chest pain centers, the implementation of ultra-fast CLIA point-of-care testing powered by CRET technology has contributed to a substantial reduction in door-to-balloon time, a critical metric in cardiac emergency care. In community health centers, the combination of the C5000 analyzer and lyophilized reagents has brought CLIA-level sensitivity to primary care settings without requiring large infrastructure investments.
In intensive care unit sepsis management, the synergy of Procalcitonin (PCT) and Interleukin-6 (IL-6) testing, both part of Poclight's inflammation and infection diagnostics menu, has accelerated clinical decision-making for rapid infection response. In decentralized women's care settings, benchtop CLIA integration has enabled lab-quality endocrine and fertility monitoring directly within clinic environments, supporting reproductive health management without the need for centralized laboratory referral.
A Broad and Flexible Testing Menu Built on CRET
The CRET platform supports quantitative biomarker detection across more than 50+ parameters, spanning inflammation and infection diagnostics, cardiovascular disease markers, thyroid function testing, fertility and hormone testing, diabetes and metabolic testing, bone metabolism and vitamin testing, tumor marker testing, respiratory diagnostics, and platelet function and coagulation-related testing. This breadth allows the same underlying technology to serve a wide range of clinical departments, including ICU, emergency, cardiology, oncology, pediatrics, primary care, gynecology, and veterinary medicine.
Why This Matters for Distributors and Healthcare Partners
For IVD distributors, medical professionals, lab directors, and veterinary hospitals evaluating diagnostic platforms, CRET technology offers a combination of reduced operational costs, simplified logistics, and maintenance-free hardware. Poclight also offers OEM/ODM services, allowing partners to integrate the CRET platform into their own product lines through technology licensing or integrated solution models. This openness extends the reach of the technology beyond direct equipment sales and reagent supply, supporting global market expansion across South Asia, Southeast Asia, the Middle East, Africa, and Latin America.
Conclusion
Choosing CRET technology means adopting a diagnostic approach engineered to remove the friction historically associated with chemiluminescence immunoassay testing: washing steps, cold chain dependency, instrument bulk, and hidden maintenance costs. Backed by patent exclusivity and multiple international certifications, Poclight Biotechnology's CRET platform, embodied in products such as the C5000 analyzer and its lyophilized reagent portfolio, offers a practical answer to longstanding pain points across clinical, primary care, and veterinary diagnostic environments, consistent with the company's stated mission of "Guarding Health with Diagnostic Innovation."
www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd